Aspect Biosystems raises $115M Series B for bioprinted tissue therapeutics targeting diabetes and metabolic disorders, led by ...

Vir Biotechnology reports early data on T cell engagers VIR-5818 and VIR-5500, licensed from Sanofi, showing tumor shrinkage ...

Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two ...

A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start ...

Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...

Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Aet­na is go­ing af­ter an­oth­er phar­ma­ceu­ti­cal com­pa­ny for al­leged price fix­ing. The health in­sur­ance provider ...

Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said ...

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech ...